Holen Sie sich die Stockscreener-App
5.84
1.39%
0.08
Handel nachbörslich:
5.93
0.09
+1.54%
Schlusskurs vom Vortag:
$5.76
Offen:
$6.1999
24-Stunden-Volumen:
21,917
Relative Volume:
1.68
Marktkapitalisierung:
$142.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.50M
KGV:
-7.5844
EPS:
-0.77
Netto-Cashflow:
$-30.10M
1W Leistung:
+34.25%
1M Leistung:
+50.52%
6M Leistung:
+84.23%
1J Leistung:
+126.36%
1-Tages-Spanne:
$5.821
$6.1999
1-Wochen-Bereich:
$4.31
$6.1999
52-Wochen-Spanne:
$2.20
$6.1999
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie EPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
5.84 | 142.68M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Trading (EPRX.WT.A) With Integrated Risk Controls - news.stocktradersdaily.com
(EPRX) Strategic Investment Report (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Canaccord Genuity Group - Defense World
Canaccord Genuity initiates Eupraxia stock with spec. buy on EoE treatment - Investing.com Canada
(EPRX.WT.A) Dynamic Trading Report - news.stocktradersdaily.com
Millennium Management LLC Invests $31,000 in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) - Defense World
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 1.1% – Should You Sell? - Defense World
When the Price of (EPRX.WT.A) Talks, People Listen - news.stocktradersdaily.com
(EPRX) Strategic Equity Report (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Market Performance Analysis - news.stocktradersdaily.com
(EPRX) Investment Report (EPRX:CA) - news.stocktradersdaily.com
Long Term Trading Analysis for (EPRX) (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 0.8% – Should You Sell? - Defense World
(EPRX) Advanced Equity Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals - TipRanks
Why Broadcom Stock Blew Past the Market on Monday - The Globe and Mail
Why Meta Platforms Stock Soared on AI News Today - The Globe and Mail
Hogs Close Mixed on Monday - The Globe and Mail
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewswire
Stocks in play: Ares Strategic Mining Inc - The Globe and Mail
Should You Buy Paylocity Stock Despite its 7% Dip in 3 Months? - The Globe and Mail
Most Anticipated Earnings this Week – Week of June 2, 2025 - The Globe and Mail
E3 Lithium Provides Progress Update for the Demonstration Facility - The Globe and Mail
(EPRX.WT.A) Stock Market Analysis - news.stocktradersdaily.com
(EPRX) Investment Strategy and Analysis (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Equity Market Report - news.stocktradersdaily.com
2 Top Stocks to Buy With Less Than $100 - The Globe and Mail
(EPRX) Market Performance Analysis (EPRX:CA) - news.stocktradersdaily.com
Definity Financial Corporation Announces Increased Size of Previously Announced Private Placements of Common Shares to $385 million - The Globe and Mail
Should You Buy High-Yield Enterprise Products Partners While It's Below $36? - The Globe and Mail
(EPRX.WT.A) Technical Patterns and Signals - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading Down 0% – Here’s What Happened - Defense World
Travel + Leisure Up 10% in a Month: Hold Steady or Lock in Gains? - The Globe and Mail
(EPRX) Strategic Market Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc - Stockhouse
(EPRX) Long Term Investment Analysis (EPRX:CA) - news.stocktradersdaily.com
Long Term Trading Analysis for (EPRX.WT.A) - news.stocktradersdaily.com
“Bear-Pit Session” Highlights Peterson Capital’s Canada Growth Conference in Montreal - The Globe and Mail
11,613 Shares in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Acquired by Raymond James Financial Inc. - Defense World
(EPRX.WT.A) Comprehensive Trading Strategy Report - news.stocktradersdaily.com
Trading (EPRX) With Integrated Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Raymond James Sticks to Its Buy Rating for Eupraxia Pharmaceuticals (EPRX) - The Globe and Mail
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - The Globe and Mail
Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Wednesday - Defense World
(EPRX.WT.A) Trading Strategy and Analysis - news.stocktradersdaily.com
Eupraxia Pharmaceuticals to Host Virtual KOL Event to - GlobeNewswire
Nova Leap Health Corp. Posts Q1 2025 Results - The Globe and Mail
Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study - TipRanks
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 - GlobeNewswire
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results - Stock Titan
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):